Treatment strategies of the thromboembolic risk in kidney failure patients with atrial fibrillation
More info: https://t.co/Z4H2WfJgBW
@NDTsocial, @vinckcaro, @hjanders_hans, @ERAkidney
A good life is largely defined by what's missing:
- The fights that don't happen
- The health problems you don't have
- The debt you avoid
- The desires you don't indulge
ใ ค
A good life's not about gaining. It's about letting go.
Bortezomib, a proteasome inhibitor, is different from other chemotherapies in the sense that it can cause two types of peripheral neuropathy: a common garden-variety distal symmetric polyneuropathy (classic chemo neuropathy) and a rare autoimmune axonal neuropathy.
Bortezomib-induced autoimmune neuropathy is usually subacute, painful, asymmetric, motor-predominant, and has axonal features on nerve conduction studies. It can present as polyradiculoneuropathy, lumbosacral radiculoplexus neuropathy, and distal polyneuropathy and continues to progress after discontinuation of the drug. Nerve biopsy may show an active neuropathy with axonal degeneration, ischemic injury, and inflammation with microvasculitis. I often treat them as LRPN with a 12-week IV methylprednisolone trial.
Our new analysis of the TESTING trial in @KIReports -
Steroids improve kidney outcomes in #IgAN at high risk of progression, irrespective of proteinuria or eGFR. But
the balance of benefits/harms may be less favourable in those with advanced CKD
https://t.co/a4wVTB0C2Y
Rationale and Design of the RENAL LIFECYCLE Trial Assessing the Effect of Dapagliflozin on Cardiorenal Outcomes in Severe Chronic Kidney Disease
~1500 patients (GFR<25, dialysis, or transplant GFR<45)
PEP: HHF or all-cause mortality (dialysis) and ESKD
https://t.co/nxNCk5YH2w
๐งต Thread 1๏ธโฃ-๐: Raw Facts You Won't Hear from the German๐ฉ๐ช Media Echo Chambers About the Latest Horrendous Terror Attack in Germany / #Magdebourg:
Early 2006:
'Taleb Abdulmohsen' flees Saudi Arabia after being accused of rape and implicated in serious crimes.
Hosting my FIRST #NephJC at 9 pm EST today! Talking about the post hoc analysis @JASN of the COMPASS trial @NEJM.
Take a peek at the summary by @MontxuLarr and VA by @RowanZyada below!
See you all soon! @NephJC
https://t.co/dfDw5JP2Q8